Citadel Advisors
ELDN icon

Citadel Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Citadel Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$851K Buy
+215,973
New +$785K ﹤0.01% 8610
2025
Q3 		– Sell
-152,460
Closed -$446K – 13061
2025
Q2 		$413K Buy
152,460
+58,463
+62% +$175K ﹤0.01% 9077
2025
Q1 		$319K Sell
93,997
-95,873
-50% -$395K ﹤0.01% 9440
2024
Q4 		$782K Buy
+189,870
New +$749K ﹤0.01% 7553
2024
Q2 		– Sell
-15,982
Closed -$32.9K – 14513
2024
Q1 		$32.9K Sell
15,982
-7,226
-31% -$12.9K ﹤0.01% 12606
2023
Q4 		$41.8K Buy
+23,208
New +$32.3K ﹤0.01% 11974
2023
Q3 		– Sell
-7,740
Closed -$10.6K – 14490
2023
Q2 		$10.6K Sell
7,740
-23,070
-75% -$48.1K ﹤0.01% 13195
2023
Q1 		$72.7K Buy
+30,810
New +$82.6K ﹤0.01% 11681
2022
Q1 		– Sell
-10,174
Closed -$39.4K – 13810
2021
Q4 		$45K Buy
+10,174
New +$51.5K ﹤0.01% 13304
2021
Q2 		– Sell
-25,062
Closed -$268K – 13830
2021
Q1 		$268K Buy
+25,062
New +$378K ﹤0.01% 11101
2020
Q3 		– Sell
-3,016
Closed -$25K – 10199
2020
Q2 		$25K Buy
+3,016
New +$34K ﹤0.01% 9502
2019
Q4 		– Sell
-3,365
Closed -$38K – 9252
2019
Q3 		$38K Buy
3,365
+1,162
+53% +$16.7K ﹤0.01% 8783
2019
Q2 		$40K Buy
+2,203
New +$96.4K ﹤0.01% 8798

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Citadel Advisors's ELDN Position: Q2 2026 in Review

Citadel Advisors opened a new position in Eledon Pharmaceuticals (ELDN) in Q2 2026: 215,973 shares worth $851K. The stake represents ﹤0.01% of the portfolio and ranks #8610 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ELDN as recently as Q2 2025.

Citadel Advisors first reported a position in ELDN in Q2 2019 and has held it in 13 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Citadel Advisors held 215,973 shares of Eledon Pharmaceuticals worth $851K as of Q2 2026.
  • Eledon Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8610 holding.
  • Citadel Advisors first reported a position in Eledon Pharmaceuticals in Q2 2019 and has held it in 13 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.